Results 301 to 310 of about 8,790,513 (336)

Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

Journal of Comparative Effectiveness Research, 2020
Aim: To investigate the cost-effectiveness of lenvatinib and sorafenib in the treatment of patients with nonresected hepatocellular carcinoma in China.
Hongfu Cai, Long-Feng Zhang, Na Li, B. Zheng, Mao-Bai Liu   +4 more
semanticscholar   +1 more source

A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).

Journal of Clinical Oncology, 2015
6621 Background: Cost effectiveness of predictive biomarkers is currently assessed by Markov Chain (MC) simulations, requiring resources and expertise.
Anton Safonov, Weiwei Shi, James Platt, Bilge Aktas, Tomoko Kurita, Lajos Pusztai, Christos Hatzis   +6 more
openaire   +1 more source

Incremental Cost-Effectiveness Ratio of Alteplase in Patients with Acute Myocardial Infarction in the French Setting

PharmacoEconomics, 1997
On the basis of data collected from general hospital centres in France on 704 patients initially presenting with acute myocardial infarction, the mean 1-year cost of treatment was calculated to be 52,160 French francs (F) per patient (1994 values). This was independent of whether the patient received thrombolysis, and included all costs associated with
A, Pelc, J, Dardenne, J H, Frelon, G, Hanania   +3 more
openaire   +2 more sources

Next-Generation Sequencing vs Culture-Based Methods for Diagnosing Periprosthetic Joint Infection After Total Knee Arthroplasty: A Cost-Effectiveness Analysis.

Journal of Arthroplasty, 2019
BACKGROUND Periprosthetic joint infection (PJI) after total knee arthroplasty is challenging to diagnose. Compared with culture-based techniques, next-generation sequencing (NGS) is more sensitive for identifying organisms but is also less specific and ...
M. Torchia, D. Austin, Samuel T Kunkel, K. Dwyer, W. Moschetti   +4 more
semanticscholar   +1 more source

Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives.

European journal of internal medicine, 2017
S. Trippoli
semanticscholar   +1 more source

Determination of incremental cost-effectiveness ratios of antitumor drugs

Farmaciya (Pharmacy), 2021
Tat'jana Sergeevna Teptsova, Kristina Andreevna Perova, Nuriya Zagitovna Musina, Vitaliy Vladimirovich Omelyanovsky, Georgiy Rubenovich Khachatryan   +4 more
openaire   +1 more source

A Cost-Effectiveness Comparison Between Open Transforaminal and Minimally Invasive Lateral Lumbar Interbody Fusions Using the Incremental Cost-Effectiveness Ratio at 2-Year Follow-up.

Neurosurgery, 2015
Gurpreet S. Gandhoke, Hangyeul Shin, Yue-Fang Chang, Zachary J. Tempel, P. Gerszten, D. Okonkwo, A. Kanter   +6 more
semanticscholar   +1 more source

A simulation study to compare methods for constructing confidence intervals for the incremental cost-effectiveness ratio

Health Services & Outcomes Research Methodology, 2007
Ming-Yu Fan, Xiao-Hua Zhou
semanticscholar   +1 more source

Decision-making with the incremental cost-effectiveness ratio under uncertainty

2006
Cet article concerne l'applicabilité des régions de confiance du ratio coût-efficacité incrémental (RCEI) à la prise de décision dans les évaluations médico-économiques, qui est loin d'être directe, car deux RCEI identiques peuvent être associés à des conclusions opposées.
de Peretti, Christian, Siani, Carole
openaire   +1 more source

Effect of time horizon on incremental cost-effectiveness ratios

2005
Background: Estimation of cost-effectiveness of a therapy as compared with another, in healthcare, is often based on a single perspective and a single time horizon. In this thesis, I explored methods of extrapolating the survival effect of different interventions and the effect of time horizon on incremental cost-effectiveness ratios when comparing two
openaire   +1 more source